Science 37 Named Market Leader for Global Decentralized Clinical Trials by Frost & Sullivan
RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™, today announced that it has been honored with the prestigious Frost & Sullivan Market Leadership Award in the global decentralized clinical trials industry. This acknowledgment highlights Science 37’s accomplishments, and solidifies its role as an industry leader, as it continues to transform clinical trial conduct through the Metasite.
Frost & Sullivan’s Best Practices Market Leadership Award is bestowed upon companies that exhibit outstanding performance and visionary approaches in their respective industries. The receipt of this prestigious award highlights Science 37’s dedication to accelerating clinical research by enabling universal trial access for patients.
“We are proud to receive the Frost & Sullivan Market Leadership Award,” said David Coman, Chief Executive Officer at Science 37. “This award highlights our continued leadership in product quality, customer satisfaction, and implementation excellence, as we continue to deliver new approaches to remote clinical research.”
“Science 37 is committed to accelerating clinical research by enabling access to patients anywhere,” said Manuel Albornoz, Best Practices Research Analyst of Frost & Sullivan. “Science 37 ensures compliance with industry standards and regulatory requirements through robust security and privacy measures and adherence to the standards set by Good Clinical Practice (GCP) regulations. The Metasite’s processes are user-friendly and standardized, resulting in greater consistency, compliance, and data accuracy.”
Science 37’s unique approach is a virtual site, or Metasite, which enables patients to participate in clinical trials from the comfort of their homes. With investigator oversight, the Metasite removes boundaries and enhances the participant experience with flexible telemedicine visits, remote data capture, and convenient scheduling times. Powered by a proprietary platform enabling eConsent, ePRO, telemedicine, scheduling, and wearable/device integration, the Metasite drives unified study orchestration, greater compliance, and high-quality data—reaching patients wherever they are. To learn more about Science 37’s Market Leadership Award, visit www.science37.com/market-leader-award.
About Science 37
Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to accelerate clinical research by enabling universal trial access for patients. Through our Metasite™ we reach an expanded population beyond the traditional site, delivering on our goal of clinical research that works for everyone—with greater patient diversity. Patients gain the flexibility to participate from the comfort of their own homes, at their local community provider, or at a traditional site when needed. Our Metasite is powered by a proprietary technology platform with in-house medical and operational experts that drive uniform study orchestration, enabling greater compliance and high-quality data. To learn more, visit www.science37.com, or email science37@science37.com.
About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the products offered by Science 37 and the markets in which it operates, and Science 37’s anticipated growth and profitability. These forward-looking statements generally are identified by the words “believe,” “can,” “could”, “seek”, “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “might”, “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the ability to maintain the listing of Science 37’s securities on The Nasdaq Stock Market LLC, (ii) volatility in the price of Science 37’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Science 37 operates, variations in performance across competitors, changes in laws and regulations affecting Science 37’s business, changes in its capital structure, and general economic and financial market conditions, including fluctuations in currency exchange rates, economic instability, and inflationary conditions (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional opportunities, (iv) the risk that Science 37 may never achieve or sustain profitability, (v) the risk that Science 37 will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all, (vi) failure to realize anticipated cost savings, and (vii) risks related to general economic and financial market conditions. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Science 37’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 6, 2023 and in the other documents filed by Science 37 from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Science 37 assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Science 37 does not give any assurance that Science 37 will achieve its expectations.
MEDIA INQUIRIES:
Grazia Mohren
Science 37
PR@science37.com
INVESTOR RELATIONS:
Steve Halper
LifeSci Advisors
Investors@science37.com
